MétaCan
Menu
Back to cohort

Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Children’s Oncology Group (COG) study AREN0532.

2015· article· en· W4255717822 on OpenAlexaff
Conrad V. Fernandez, Elizabeth A. Mullen, Peter F. Ehrlich, John A. Kalapurakal, Geetika Khanna, Yueh‐Yun Chi, Elizabeth J. Perlman, Arnold Paulino, Thomas E. Hamilton, Kenneth W. Gow, Fernando Ferrer, Zelig Tochner, Qi An, Fredric A. Hoffer, Janice S. Withycombe, Robert C. Shamberger, James I. Geller, James Robert Anderson, Paul E. Grundy, Jeffrey S. Dome

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicRenal and related cancers
Canadian institutionsAlberta HealthIzaak Walton Killam Health Centre
Fundersnot available
KeywordsCogMedicineWilms' tumorOncologyStage (stratigraphy)Internal medicineHistologyWilms tumourPediatric oncologyCancer

Abstract

fetched live from OpenAlex

10010 Background: National Wilms Tumor Study 5 showed an inferior outcome for stage III FHWT patients with combined Loss of Heterozygosity (LOH) at chromosomes 1p and 16q when treated with Regimen DD4A (vincristine/dactinomycin/doxorubicin/radiation therapy (RT)). Patients with combined LOH were thus treated with increased therapy on COG study AREN0533. We evaluated the outcomes and prognostic utility of clinical and biological variables for the remaining stage III FHWT patients. Methods: From October 2006 to August 2013, 583 eligible patients met COG stage III criteria on central review of pathology, diagnostic imaging and surgical reports. Forty patients found to have combined LOH 1p and 16q were excluded from the survival analysis. All patients received DD4A; those with anaplasia at delayed nephrectomy were removed from protocol therapy. Tumor 1p and 16q LOH status was determined by microsatellite analysis. Results: Median follow up was 42 months (1.5-90). Median age at diagnosis was 45 months (range 1.4-220); 381 (70%) were white. Median tumor weight was 550 grams (22-3140). The 4-year event-free survival (EFS) and OS estimates were 88% (95%CI: 85-91%) and 96% (95%CI 93-98%), respectively. Fifty-eight out of 62 events occurred in the first 2 years. Site of relapse: lung +/- other (n = 35), abdomen or pelvis (n = 5), liver (n = 5), other (n = 15). Causes of death: relapse (n = 12), toxicity (n = 2), second malignancy (n = 1), non-cancer death (n = 1), other (n = 1). 123/543 (23%) had delayed nephrectomy. Submitted delayed nephrectomy histology showed: Anaplasia (n = 8); Low Risk/completely necrotic (n = 5; 0 relapses), Intermediate risk (n = 54; 6 relapses), High-Risk/Blastemal Type (n = 4; 4 relapses) and Indeterminate (n = 2; 2 relapses). Other prognostic variables examined in the table below. Conclusions: Most stage III FHWT patients had very good EFS and OS with DD4A and RT. Lymph node status, post-chemotherapy histology, and LOH were predictive of EFS. Future trials should consider modifying therapy based on identified prognostic markers. Clinical trial information: NCT00352534. n EFS P value OS P value Lymph Nodes Negative 237 95% < 0.01 98% 0.18 Positive 152 83% 95% Gross residual disease Negative 394 89% 0.14 97% 0.39 Positive 134 85% 93% LOH Neither 382 92% < 0.01 97% 0.55 16q only 99 83% 97% 1p only 56 74% 93%

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.009
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.098
GPT teacher head0.419
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicRenal and related cancersFrench-language works237,207